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Abstract
Supercentenarians (aged 110 years old or more) are extremely rare in the world population (the number of living
supercentenarians is estimated as 47 in the world), and details about their neuropathological information are
limited. Based on previous studies, centenarians (aged 100–109 years old) exhibit several types of neuropathological
changes, such as Alzheimer’s disease and Lewy body disease pathology, primary age-related tauopathy, TDP-43
pathology, and hippocampal sclerosis. In the present study, we provide results from neuropathological analyses of
four supercentenarian autopsy cases using conventional and immunohistochemical analysis for neurodegenerative
disorders. In particular, we focused on the pathology of Alzheimer’s disease and Lewy body disease, as well as the
status of hippocampal sclerosis, TDP-43 pathology, aging-related tau astrogliopathy, and cerebrovascular diseases.
Three cases were characterized as an “intermediate” level of Alzheimer’s disease changes (NIA-AA guideline) and
one was characterized as primary age-related tauopathy. TDP-43 deposits were present in the hippocampus in two
cases. Neither Lewy body pathology nor hippocampal sclerosis was observed. Aging-related tau astrogliopathy was
consistently observed, particularly in the basal forebrain. Small vessel diseases were also present, but they were
relatively mild for cerebral amyloid-beta angiopathy and arteriolosclerosis. Although our study involved a small
number of cases, the results provide a better understanding about human longevity. Neuropathological alterations
associated with aging were mild to moderate in the supercentenarian brain, suggesting that these individuals
might have some neuroprotective factors against aging. Future prospective studies and extensive molecular
analyses are needed to determine the mechanisms of human longevity.
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Introduction
Increased human longevity is a goal in many parts of the
world. Although it is difficult to clearly define “successful
aging,” aging without any severe diseases or disabilities is
ideal. Among the many factors associated with a decreased
ability to function during human aging, brain disease is an
important factor. According to epidemiological data, the
number of centenarians (aged 100 or more) in the world
was 451,000 in 2015 (http://esa.un.org/unpd/wpp/Down-
load/Standard/Population; World Population Prospects,
2015 revision). Additionally, this number could increase to
3,678,000 by 2050 (http://esa.un.org/unpd/wpp/Download/
Standard/Population; World Population Prospects, 2015
revision). Neuropathological analyses of centenarian brains
remain limited. From a Japanese cohort, centenarian brains
exhibited Alzheimer’s disease (AD) and cerebrovascular dis-
ease (CVD), as well as cases with no definite pathological
alterations [1]. Based on our introductory analysis of 58
centenarian brains (mean age 101.5 ± 1.7 y), a high likeli-
hood of intermediate AD pathology (NIA Reagan criteria)
was observed in 15 cases (25.8 %) and a low likelihood of
sparse neuritic plaques and stage I/II of Braak staging of
neurofibrillary tangles was observed in 8 cases (13.7 %).
Additionally, 21 cases (36.2 %) were characterized as pri-
mary age-related tauopathy (PART), which was recently
recognized as a neuropathological condition of the aging
brain. Recent published neuropathological data from three
cohorts in the US and UK showed that AD pathology is
not common [2]. Hippocampal sclerosis-related aging and
Lewy body pathology were reported, and arteriolosclerosis
was shown to be possibly associated with hippocampus
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sclerosis-related aging [2, 3]. Therefore, those centenarian
cases may exhibit high proportions of AD pathology, as
well as non-AD pathology. However, the average age of in-
dividuals analyzed in those studies was close to 100 years.
In autosomal-dominant cases of AD, the onset of amyloid-
beta deposition might be 15 years prior to the onset of clin-
ical symptoms [4]. Therefore, centenarians close to
100 years of age with AD pathology might represent indi-
viduals who developed pathological AD changes between
80 and 90 years of age.
Compared with centenarians, supercentenarians (aged
110 years old or more) are extremely rare in the human
race. According to a study by the “Gerontology Research
Group” in 2016, the number of living supercentenarians
is estimated as 47 in the world (http://supercentenarian-
research-foundation.org/TableE.aspx, accessed July 14,
2016). However, it is difficult to estimate the actual
number of worldwide supercentenarians, because some
individuals lack a birth certificate or, depending on the
country of origin, it might be difficult to obtain a reliable
birth certificate. Therefore, systematic neuropathological
analysis of supercentenarian brains remains difficult. We
have attempted to locate supercentenarians and commu-
nicate with their families to obtain brain samples for
pathological analyses. Clarification of the neuropatho-
logical conditions of these exceptional humans might
provide a better understanding of the pathomechanisms
involved in human longevity.
A previous clinical and neuropathological study of a
115-year-old woman from the Netherlands [5] reported
well-preserved cognitive function, with only mild aging
alterations. In the present study, we provide results from
neuropathological analyses of four supercentenarian aut-
opsy cases using conventional and immunohistochemical
analysis for neurodegenerative disorders. In particular,
we focused on the pathology of AD and Lewy body dis-
ease, as well as the status of hippocampal sclerosis,




All individuals were contacted by one (NH) of the au-
thors prior to death. At that time, clinical conditions
and some medical anamnesis were obtained from each
individual and their relatives, as well as their caregivers.
Blood samples were obtained for future analyses. To
confirm the age of individuals, the date of birth was de-
termined using the family register. Apolipoprotein E
(APOE) genotyping was also determined.
Autopsy
Because the individuals were placed in elderly care facil-
ities, the bodies were transferred from the facilities to
our brain bank by hospital ambulance following death.
At the time of autopsy, fresh brain tissue was dissected
at the mid-sagittal line. The right cerebrum, cerebellum,
and brainstem were immediately frozen by dry ice and
stored at −80 °C for future studies. The left hemisphere
of the brain was fixed in 20 % neutral-buffered formalin
(Wako, Osaka, Japan) for neuropathological analysis.
Neuropathological studies
Neuropathological studies were performed on postmortem
tissue from four individuals (Table 1). All cases were regis-
tered with our Brain Bank and neuropathologically ana-
lyzed according to the following protocols. Samples were
dissected from coronal slices of fixed brains from the fol-
lowing regions: superior and middle frontal gyri, anterior
cingulate gyrus, superior and middle temporal gyri, motor
and sensory cortices, insular cortex, calcarine cortex, amyg-
dala, hippocampus, subiculum, parahippocampal gyrus,
caudate nucleus, putamen, globus pallidus, thalamus, cere-
bellum, midbrain, pons, and medulla [6, 7]. Blocks were
dehydrated in alcohol gradients, cleared in xylene, and em-
bedded in paraffin. The brain tissues were cut into 6-μm-
thick sections. The sections were stained with hematoxylin
and eosin (HE), Klüver-Barrera for myelin, and modified
Gallyas-Braak silver staining for fibrils. For immunohisto-
chemical studies, monoclonal antibodies specific to amyloid
Aβ (11–28) (12B8, 1:100, IBL, Gunma, Japan), phospho-tau
(AT8, 1:3000, Innogenetics, Ghent, Belgium), 4-repeat iso-
form tau (RD4, 1:500, 1E1/A6, Merck Millipore, Darmstadt,
Germany), 3-repeat isoform tau (RD3, 1:500, 8E6/C11,
Merck Millipore), phosphorylatedα-synuclein (1:7000,
pSyn#64, monoclonal, Wako), and phosph-TDP-43 (s409/
410, 1:7000, COSMO BIO, Tokyo, Japan) were used. The
sections were processed using a Ventana Discovery auto-
mated immunostainer (Roche, Basel, Switzerland), and the
sections were counterstained with hematoxylin.
For neuropathological diagnosis of Alzheimer’s disease,
we used the Consortium to Establish a Registry for Alz-
heimer’s Disease (CERAD) methodologies, widely ap-
plied to make a diagnosis of Alzheimer’s disease, as a
guide for analyzing the frequency of neuritic plaques [8].
Braak staging of neurofibrillary tangle formation and
Thal phase of amyloid beta were also used [9–11]. Even-
tually, National Institute on Aging (NIA)-Reagan criteria
(1997) and NIA-Alzheimer’s Association (NIA-AA)
guidelines (2012) were applied for determining the level
of AD pathological change [12, 13]. Those neuropatho-
logical strategies also allowed us to identify whether each
case corresponded with PART criteria.
The ARTAG type and anatomical areas were analyzed
in all sections according to a recently published harmo-
nized evaluation strategy using AT8 immunohistochemis-
try [14]. First, AT8 immunoreactive thorn-shaped
astrocytes (TSA) and fine granular immunoreactivity
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(GFA) were identified. Second, the type, major anatomical
involvement, severity, and detailed regional distribution
were determined [14]. TDP-43 immunoreactivity was clas-
sified as neuronal cytoplasmic (NCI), neuronal nuclear
(NNI), and glial cytoplasmic (GCI) immunoreactive de-
posits, as well as neurites.
Cerebral amyloid angiopathy and arteriolosclerosis, as
well as white matter rarefaction and état criblé, were
assessed using a subjective scale of none, mild, moderate
or severe.
We obtained written informed consent from the relatives
of the deceased for autopsy and further neuropathological
analysis, and all subjects were registered with our brain
bank for future research. The brain bank was approved by




All four supercentenarian individuals were female. Be-
cause they were placed in elderly care facilities, the indi-
viduals did not receive extensive medical treatment
during the end stages of life. It was difficult to determine
whether they were demented at the time of interview.
Table 1 Patient demographics and summary of neuropathological analyses
Case 1 (111 yo) Case 2 (111 yo) Case 3 (114 yo) Case 4 (110 yo)
Sex Female Female Female Female
Past medical history HT-, DM- HT-, DM- HT-, DM- HT+, DM-
Clinical condition before
death

























Cause of death Heart failure Renal failure Senility Sepsis
APOE 2/3 2/3 3/3 3/3
Brain weight (fresh) 460 (left hemisphere) 925 1,015 1,115
Atrophy F, T F, T F, T T
A-beta, Thal phase 3 (A2) 3 (A2) 1 (A1) 2 (A1)
NFT stage (AT8) (Braak) III (B2) IV (B2) III (B2) IV (B2)
Neuritic plaques (CERAD) Moderate (C2) Moderate (C2) Sparse (C1) Moderate (C2)
CAA None None None Mild
AD pathological changes
(NIA-Reagan)














Arteriolosclerosis Mild to moderate Mild to moderate Mild to moderate Mild to moderate
White matter rarefaction Moderate Mild Mild Moderate
État criblé (basal ganglia
and thalamus)
Moderate Severe Severe Moderate
Vascular brain injury Multiple cortical infarcts None None None
Alpha-synuclein
pathology
None None None None
TDP-43 pathology Present, subiculum, PHG Present, subiculum,
PHG
Uncus, sparse Uncus, sparse
Hippocampal sclerosis None None None None
Hirano bodies/GVD
(Hippocampus)
Present/present Present/present Present/present Present/present
Abbreviations: ARTAG aging-related tau astrogliopathy, CAA cerebral amyloid angiopathy, CDR Clinical Dementia Rating, CERAD Consortium to Establish a Registry
for Alzheimer’s Disease, DM diabetes mellitus, F frontal lobe, GVD granulovaculaor degeneration, HT hypertension, MMSE Mini-Mental State Examination, NA not
available, NIA National Institute on Aging, NIA-AA NIA-Alzheimer’s Association, T temporal lobe, yo years old
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Case 1 was able to communicate and move her wheel-
chair herself. In Case 2, no apparent dementia symptoms
were reported by the nursing staff. Cases 3 and 4 were
able to communicate with other people and manipulate
their wheel chairs. In some individuals, Barthel index,
clinical dementia rating (CDR) scale and Mini-Mental
State Examination (MMSE) were evaluated (Table 1).
The clinical characteristics are summarized in Table 1.
Neuropathology
Because brain pathology of supercentenarians has not
been previously well described, we report descriptive
neuropathological findings from each case. The sum-
mary of neuropathological findings is shown in Table 1.
Case 1
Gross neuropathology
The fresh brain weight of the left hemisphere was 460
grams. Unfortunately, the right cerebral hemisphere (frozen
side) was not weighed at the time of autopsy. After formalin
fixation, there was mild atrophy in the frontal and temporal
lobes (Figs. 1a and 2a). Atherosclerosis was mild in the
major cerebral arteries. No atheromatous plaques were seen
in the leptomeningeal vessels. On the coronal sections, a
mild enlargement was present at the posterior part of lat-
eral ventricle. No atrophy was seen in the cerebellum. The
substantia nigra and locus coeruleus were well pigmented.
Microscopic neuropathology
Neuronal loss and gliosis was none to mild in the majority
of the cerebral cortex. Neurons in the substantia nigra and
locus coeruleus were well preserved. Moderate numbers of
Aß-immunoreactive neuritic plaques were observed using
CERAD methodology. Aß-immunoreactive parenchymal
deposits were characterized as phase 3 using Thal’s meth-
odology. There was also a moderate level of Aß-immuno-
reactive diffuse plaques observed, although no Aß-
immunoreactive cerebral amyloid angiopathy was seen.
AT8-immunoreactive NFTs were stage III according to
Braak methodology (Figs. 3a and 4a, Table 1). Therefore,
Case 1 was assigned an intermediate level of AD patho-
logical changes according to NIA-Reagan and NIA-AA cri-
teria. Alpha-synuclein immunoreactive deposits, as well as
AT8-immunoreactive tufted astrocytes and astrocytic pla-
ques, were not observed. All ARTAG types were mainly
observed in the medal temporal lobe and subcortical areas.
The perivascular ARTAG pattern was particularly present
in the basal forebrain (Figs. 5 and 7). No hippocampal
sclerosis was observed. TDP-43-immunoreactive NCIs and
neuritis were present in the basal forebrain, hippocampus,
and subiculum (Fig. 6, Table 2). NNIs and GCIs were also
present (Table 2). In the parietal cortex, there was a small
area with neuronal loss, with gliosis and hemosiderin-laden
macrophages in the cortex. These findings were consistent
with an old hemorrhagic infarct. A small vessel occluded
by an organizing thrombus was seen in the subarachnoid
space immediately adjacent to the infarct. Because there
were no atherosclerotic changes in the leptomeningeal ves-
sels, the infarct was considered to be an embolic lesion.
Mild to moderate arteriolosclerosis was observed in vari-
ous areas (Table 3). Mineralization was seen in the small
vessel wall in the globus pallidus (Fig. 9a).
Fig. 1 Photomicrographs of fixed left-brain hemispheres from four supercentenarians. Mild atrophy is present in the frontal and/or temporal
lobes. a Case 1, (b) Case 2, (c) Case 3, (d) Case 4. Bar = 2 cm
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Case 2
Gross neuropathology
The fresh brain from Case 2 weighed 925 grams. After
formalin fixation, there was mild atrophy in the frontal
lobe and moderate atrophy in the temporal lobes
(Fig. 1b). Atherosclerosis was mild in the major cerebral
arteries. No atheromatous plaques were seen in the
leptomeningeal vessels. On coronal sections, there were
no focal lesions except mild enlargement of the lateral
ventricle (Fig. 2b). Subcortical nuclei were well preserved
without obvious atrophy. No atrophy was seen in the
cerebellum. The substantia nigra and locus coeruleus
were well pigmented.
Microscopic neuropathology
Neuronal loss and gliosis was none to mild in the majority
of the cerebral cortex. Neurons in the substantia nigra and
locus coeruleus were well preserved. Levels of Aß-immuno-
reactive neuritic plaques and parenchymal deposits were
determined moderate by CERAD and phase 3 by Thal’s sta-
ging methodology, respectively. There were also sparse
levels of Aß-immunoreactive diffuse plaques observed, but
no Aß-immunoreactive cerebral amyloid angiopathy was
observed. AT8-immunoreactive NFTs were stage IV ac-
cording to Braak methodology. Therefore, Case 2 was
assigned to an intermediate level of AD pathological
changes according to NIA-Reagan and NIA-AA criteria
Fig. 2 Coronal sections at the basal ganglia and hippocampus level. Cortical ribbons and cerebral white matter are well-preserved. Small cortical
infarct in Case 1 (a). a Case 1, (b) Case 2, (c) Case 3, (d) Case 4. Bar = 1 cm
Fig. 3 Photomicrographs of the temporal cortices from four cases. Immunohistochemistry using monoclonal antibody specific to Aβ (11–28).
a Case 1, (b) Case 2, (c) Case 3, (d) Case 4. Bar = 100 μm
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Fig. 4 Photomicrographs of hippocampus and parahippocampus from four cases. Immunohistochemistry using monoclonal antibody specific to
p-tau (AT8). a Case 1, (b) Case 2, (c) Case 3, (d) Case 4. Bar = 50 μm
Fig. 5 ARTAG of Case 1. ARTAG (thorn-shaped astrocytes) is present in the subpial areas of inferior temporal gyrus (a), white matter close to the
lateral ventricle of the hippocampus (b), and perivascular area of the basal forebrain (c, d). Immunohistochemistry using monoclonal antibody
specific to p-tau (AT8). Bar = 50 μm (a, b, d). Bar = 1000 μm (c)
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(Table 1, Figs. 3b and 4b). Alpha-synuclein immunoreactive
deposits and hippocampal sclerosis were not observed, and
there were no AT8-immunoreactive tufted astrocytes or
astrocytic plaques. ARTAGs were observed in the following
regions: 1) subpial/lobar, subcortical/frontal, and basal fore-
brain, 2) gray matter/subcortical/basal forebrain, and 3)
white matter/lobar/lateral temporal (Figs. 7 and 8). The
astrocytic tau deposits in the frontal cortex were not associ-
ated with Aß deposits. TDP-43-immunoreactive NCIs and
neuritis were moderately observed in the hippocampus and
subiculum, and GCIs were also seen (Table 2). Mild to
moderate arteriolosclerosis was observed (Table 3). The
basal ganglia exhibited severe état criblé (Fig. 9b).
Case 3
Gross neuropathology
The fresh brain from Case 3 weighed 1015 grams. After
formalin fixation, mild atrophy at the frontal and temporal
lobes was observed (Fig. 1c). Atherosclerosis was mild in
the major cerebral arteries, and no atheromatous plaques
were seen in the leptomeningeal vessels. On coronal sec-
tions, there were no focal lesions, but mild enlargement of
the lateral ventricle was observed (Fig. 2c). Subcortical nu-
clei were well preserved without obvious atrophy, and atro-
phy was not observed in the cerebellum. The substantia
nigra and locus coeruleus were well pigmented.
Microscopic neuropathology
Neuronal loss and gliosis was none to mild in the major-
ity of the cerebral cortex. Neurons in the substantia
nigra and locus coeruleus were well preserved. The level
of Aß-immunoreactive neuritic and diffuse plaques was
determined to be sparse according to CERAD method-
ology. Aß-immunoreactive parenchymal deposits were
deemed phase 1 using Thal’s methodology. No Aß-im-
munoreactive cerebral amyloid angiopathy was observed,
and AT8-immunoreactive NFTs were stage III according
to Braak methodology. Therefore, Case 3 was assigned
Fig. 6 TDP-43 pathology in the subiculum (a) and basal forebrain (b) from Case 1. Neuronal cytoplasmic inclusions and neurites are visible. TDP-
43 immunohistochemistry. Bar = 100 μm (a). Bar = 50 μm (b)
Table 2 Severity and distribution of TDP-43-immunoreactive deposition
Areas Case 1 Case 2 Case 3 Case 4
NCI Neurites NNI GCI NCI Neurites NNI GCI NCI Neurites NNI GCI NCI Neurites NNI GCI




- + - - - - - - - - - - - -
Temporal lobe - - - - - - - - - - - - - - - -

















- + - - - - - - - -
Motor cortex - - - - - - - - - - - - - - - -
Midbrain - - - - - - - - - - - - - - - -
Medulla - - - - - - - - - - - - - - - -
Spinal cord - - - - - - - - - - - - - - - -
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an unclassified level of AD pathological changes accord-
ing to NIA-Reagan criteria and low level according to
NIA-AA criteria (Table 1, Figs. 3c and 4c). This patho-
logical pattern was consistent with “PART possible”
(NFT stage 3, Thal phase 1) [15]. ARTAGs were classi-
fied as follows: 1) subpial/MTL/uncus, 2) gray matter/
MTL and subcortical/hippocampus and basal forebrain,
and 3) white matter/MTL/uncus (Figs. 7 and 10). There
were also no AT8-immunoreactive tufted astrocytes or
astrocytic plaques, as well as no alpha-synuclein-
immunoreactive deposits, and no hippocampal sclerosis
was observed. Some TDP-43-immunoreactive neuritis
was sparsely seen in the uncus (Table 2). Mild to
moderate arteriolosclerosis and état criblé were also ob-
served (Fig. 9c, Table 3).
Case 4
Gross neuropathology
The fresh brain of Case 4 weighed 1115 grams. After
formalin fixation, mild atrophy in the temporal lobe
was observed (Fig. 1d). Mild atherosclerosis was seen
in the major cerebral arteries, but atheromatous pla-
ques were not observed in the leptomeningeal ves-
sels. On coronal sections, focal lesions were not
observed, but there was mild enlargement of the lat-
eral ventricle. Although the subcortical nuclei were
Table 3 Small vessel disease and white matter rarefaction
Arteriolosclerosis White matter rarefaction
état criblé (basal ganglia and thalamus)
Case 1 Case 2 Case 3 Case 4 Case 1 Case 2 Case 3 Case 4
Frontal 2 2 1 2 2 0 1 2
Temporal 1 2 1 2 2 0 0 2
Parietal 2 1 2 1 2 1 1 1
Occipital 2 1 0 2 2 0 0 1
Hippocampus 1 1 1 1 1 0 1 1
Basal ganglia 2 2 2 2 2 3 3 2
Thalamus 2 2 2 2 2 2 2 2
Cerebellum 2 2 2 2 0 1 0 1
Instead of white matter rarefaction, the severity of état criblé was analyzed in the basal ganglia and thalamus
0: none, 1: mild, 2: moderate, 3: severe




Detailed regional distribution and studied on pathogenesis
Subpial
MTL Inf. Temporal gy. Hippocampus Amygdala Uncus
Lobar Frontal Parietal Occipital Lat. Temporal
Subcortical Basal forebrain
Brainstem Mesencephalopn Pons Medulla
Subependymal
MTL Temporal horn
Lobar LV. Frontal horn LV,. Occipital horn
Subcortical LV. Caudate 3V. Thalamus
Brainstem Aq. Mesencephalon Aq. Pons Aq. Medulla
Gray matter
MTL Inf. Temporal gy. Hippocampus Amygdala
Lobar Frontal Parietal Occipital Lat. Temporal
Subcortical Accumbens Caud/Put GP Basal forebrain
Brainstem Substantia nigra Pons Medulla
White matter
MTL Inf. Temporal gy. Hippocampus Amygdala uncus
Lobar Frontal Parietal Occipital Lat. Temporal
Subcortical Int. capsule Subinsular Pencil fiber
Brainstem Cerebral peduncli Pyramids Midline
Perivascular
MTL Inf. Temporal gy. Hippocampus Amygdala
Lobar Frontal Parietal Occipital Lat. Temporal
Subcortical Accumbens Caud/Put GP Basal forebrain





Fig. 7 Distribution and severity of ARTAG pathology in four cases. The basal forebrain is a relatively commonly affected area
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well preserved, there were some small lacunes in the
basal ganglia. No atrophy was seen in the cerebel-
lum, and the substantia nigra and locus coeruleus
were well pigmented. A small parenchymal
hemorrhage (<3 mm) was present in the middle
pontine base.
Microscopic neuropathology
Neuronal loss and gliosis was none to mild in the majority
of the cerebral cortex. Neurons in the substantia nigra and
locus coeruleus were well preserved. Aß-immunoreactive
neuritic and diffuse plaque scores were moderate and fre-
quent according to CERAD methodology, respectively. Aß-
Fig. 8 ARTAG of Case 2. ARTAG (thorn-shaped astrocytes) is present in subpial areas of the basal forebrain (a). Granular or fuzzy astrocytes (GFA) are
seen in the frontal (b) and occipital (c) cortex. In rare instances, possible GFAs are seen in the temporal white matter (d). Immunohistochemistry using
monoclonal antibody specific to p-tau (AT8). Bar = 50 μm
Fig. 9 Representative photomicrographs of small-vessel disease (arteriolosclerosis) and état criblé (a–d). Mineralization is seen in Case 1 (a). État
criblé is seen in the basal ganglia and thalamus (b and c). a Case 1: globus pallidus, (b) Case 2: thalamus, (c) Case 3: putamen, (d) Case 4: globus
pallidus. Bar = 50 μm
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immunoreactive parenchymal deposits were classified as
phase 2 according to Thal’s methodology. Aß-immunoreac-
tive cerebral amyloid angiopathy was mildly observed in
the parenchymal and leptomeningeal small vessels in the
occipital lobe, and AT8-immunoreactive NFTs were consid-
ered stage IV using Braak methodology. Therefore, Case 4
was assigned an intermediate level of AD pathological
changes according to NIA-Reagan and NIA-AA criteria.
There were no AT8-immunoreactive tufted astrocytes or
astrocytic plaques. ARTAGs were classified as follows: 1)
subpial/subcortical/basal forebrain, 2) subependymal/MTL/
temporal lobes, subependymal/lobar/LV of occipital horn,
3) gray matter/lobar/frontal, and 4) perivascular/subcor-
tical/basal forebrain. In all four cases, ARTAG was strongly
immunoreactive with AT8 (Figs. 7 and 11). In some in-
stances, ARTAG was also immunoreactive to RD4 anti-
body, but less depicted by the Gallyas-Braak staining
(Fig. 11). This ARTAG immunoreactivity was similar to
Cases 1, 2 and 3. Alpha-synuclein-immunoreactive deposits
and hippocampal sclerosis were not observed. TDP-43-
immunoreactive GCIs were sparsely observed in the uncus
(Table 2), and mild to moderate arteriolosclerosis was ob-
served (Fig. 9d, Table 3).
Discussion
The present study provides neuropathological results
from four supercentenarians (≥110 years of age) using
conventional and immunohistochemical methods. We
emphasize that this novel study is the first unique op-
portunity to comprehensively determine neuropatho-
logical conditions in four supercentenarians. We also
introduce NIA diagnostic methodology for Alzheimer’s
disease, revealing TDP-43 and ARTAG pathology in
those cases. Compared with centenarians, there are cur-
rently approximately 50 living supercentenarians in the
world (www.grg.org, last updated, July 14, 2016). We
Fig. 10 ARTAG of Case 3. ARTAG (thorn-shaped astrocytes) is present in white matter close to the hippocampus (a). GFAs are seen in gray matter
of the basal forebrain (b) and CA4 (c). Immunohistochemistry using monoclonal antibody specific to p-tau (AT8). Bar = 50 μm
Fig. 11 ARTAG of Case 4. ARTAG (thorn-shaped astrocytes) is present in the perivascular area of the basal forebrain (a), white matter close to the
lateral ventricle of the occipital lobe (b), and the lateral ventricle of the medial temporal lobe (d, e, f). GFA is seen in the superior frontal gyrus (c).
Immunohistochemistry using monoclonal antibody AT8 (a–d) and RD4 (e). Modified Gallyas-Braak stain (f). Bar = 50 μm
Takao et al. Acta Neuropathologica Communications  (2016) 4:97 Page 10 of 14
believe that supercentenarians are exceptionally distinct
human beings, and the study of this cohort is important
for understanding the mechanisms of successful aging.
Clinical information
Because our studies did not perform precise neurological
or neuropsychological studies, it was difficult to clinic-
ally determine whether the four cases experienced de-
mentia. However, the cases exhibited a certain degree of
independence during the last stages of life.
Gender and race might play a role in human longevity.
As shown in our results, all four cases were Japanese
woman. According to data from the Gerontology Re-
search Group (www.grg.org, last updated, July 14, 2016),
most living supercentenarians are women (45/47 individ-
uals). Even in the deceased supercentenarian cohort, the
number of men is low, suggesting that it is more difficult
for men to reach the supercentenarian age.
Women are considered to be at higher risk of Alzhei-
mer’s disease than men [16, 17]. In previous studies, the
rate of dementia increases in women aged > 90 years
[18–21]. In a 90+ study, the incidence of dementia in-
creased exponentially with age, reaching 40.7 % (10.9 %
men, 38.3 % women) in centenarians [17]. However, gen-
der differences were not observed ≥ 90 years of age [22].
In one study, the incidence of dementia decreased after
97 years of age in women [23].
In centenarian studies, the prevalence of dementia was
27–79 % [24–31]. Conversely, other studies have shown
that 37 % of centenarians do not exhibit dementia [32]
and may have high cognitive function [24, 33]. This dis-
crepancy between dementia rates may be associated with
different methods and samples, as well as selection
biases [24]. However, researchers should take care with
the relatively low prevalence of dementia in those cente-
narians as there may be some underestimation [18].
Although four supercentenarians were not clinically
considered to exhibit dementia conditions in the present
study, they had low MMSE scores. However, visual and
hearing impairments pose problems when applying the
MMSE test for extremely old individuals [32]. In fact,
Case 1 refused to undergo the MMSE test at the time of
interview. This suggests that a discrepancy might be
present between MMSE and CDR scores in centenarians
[32]. Whether MMSE was appropriate for this individual
remains unclear. This was further complicated by the
fact that Cases 2 and 3 were classified as dementia based
on only MMSE scores. Although neuropathological
alterations in these four cases likely played a role in cog-
nitive impairment and motor dysfunction, a more pre-
cise prospective analysis is needed for extremely old
individuals.
Although a previous case report of a female supercen-
tenarian mentioned well-preserved cognitive function
[5], the definition of dementia in such extremely aged
individuals remains unclear. At this point, we have not
validated neuropsychological examinations for the ex-
tremely elderly or standard scores for commonly used
tests, such as the Mini-Mental State Examination and
Frontal Assessment Battery.
Although the Japanese population is considered to
have long longevity, there is no strong scientific evidence
that longevity is associated with a specific ethnicity or
race. In Alzheimer’s disease, many kinds of protective
factors have been reported [34]. Although we questioned
the relatives about lifestyle and diet factors, we were not
able to identify specific factors. The individuals were
very physically active and participated in social activities
in a positive manner. Future prospective studies of
supercentenarians are needed to recruit individuals in
their 90s and centenarians.
Apo E genotype
GWAS studies have shown that the ApoE gene is
strongly associated with human longevity [35, 36]. In
particular, the ε2 allele is enriched in centenarians, com-
pared with ε4 [37]. In the present study, the ε4 allele
was not detected in any of the cases. Although more
cases are needed to substantiate our hypothesis, results
from the present study suggests that it might be difficult
for individuals expressing the ε4 allele to reach a super-
centenarian age. Because the ε2 allele is considered to be
important for protection of Aβ deposition [38], results
from two of our cases suggests that the ε2 allele may
affect brain pathology.
Neuropathology
The neuropathological results from the present study
provide unique and imperative findings of brain condi-
tions in supercentenarians. The well-preserved brain
shapes and weights in the gross neuropathological find-
ings were surprising. In all cases, there was only mild at-
rophy in the frontal and/or temporal lobes. Previous
results have shown that brain weight is affected by the
presence of brain diseases, as well as individual height
and gender [39]. Although we could not evaluate the
exact height of each individual, the cases were relatively
small or of average stature for aged Japanese females.
Based on our previous analysis, the mean brain weight
of female centenarians (mean age of 101) was 1066
grams (American Association of Neuropathologists, Inc.,
The 91st Annual Meeting, 2015 Denver, CO. Abstract
No. 129). A recent U.S. study also reported that the
unfixed brain weight of centenarians is 1000 to 1200
grams [40]. Unfortunately, there is no previous informa-
tion for the average brain weight of supercentenarians.
Nevertheless, we believe that brain weight in these four
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supercentenarians, in particular Cases 3 and 4, was rela-
tively well-preserved.
Mild atherosclerosis of the major cerebral arteries
might be a characteristic feature of supercentenarians. In
Case 1, multiple small cortical infarcts with occluded
leptomeningeal vessels were observed. Although those
infarcts were possibly due to embolic stroke, we were
not able to identify the embolism source. Once an indi-
vidual experiences a major cerebrovascular accident or
atherosclerosis of the intracranial cerebral arteries, the
clinical prognosis is typically not good [41]. In fact,
stroke is one of the most important causes of death and
disability worldwide [42]. Results from this study suggest
that well-preserved intracranial arteries might be an im-
portant element associated with human longevity.
The microscopic findings were also impressive in the
four cases. None of them exhibited high-likelihood levels
of AD pathology. In one case (Case 3), only low levels of
AD changes were observed (Table 1). As stated earlier,
age and female sex are generally considered to be risk
factors for developing AD [16, 17, 40, 43]. Further, fe-
males typically live longer than males, which could in-
crease the risk for developing AD. However, this
universal concept has not been extrapolated to super-
centenarians, who might have a biological condition that
protects against increased tau and Aβ accumulation in
the brain.
Primary age-related tauopathy (PART) was recently in-
troduced to describe a pathology commonly observed in
the brains of aged individuals [3]. PART is microscopic-
ally defined as NFTs with Braak stage ≤ IV (usually III or
lower) and Thal Aβ phase 0 (definite) or 1–2 (possible)
[3, 15, 44]. In the present study, one case (Case 3) was
assigned PART possible. Studies have discussed whether
PART is an independent condition or a characteristic of
AD [44–46]. At least in our study of PART supercente-
narians, there were very few neuritic plaques, and the
plaques exhibited an early Thal’s phase of Aß deposition,
even at the age of 114 years. It is not currently possible
to determine whether extremely aged individuals will
also suffer from AD in the future. Further analysis of
these brains could provide a better understanding as to
how humans can protect against the progression of AD
pathology.
ARTAG was recently determined to be a pathological
astrocytic condition involving tau accumulation [14].
ARTAGs include not only thorn-shaped astrocytes and
granular or fuzzy astrocytes, but also other forms of
ARTAG that do not include disease-specific astrocytic
tau pathologies, such as tufted astrocytes, astrocytic pla-
ques, ramified astrocytes, or globular astrocytic tau. In
our supercentenarians, the medial temporal lobes and
basal forebrain were relatively common areas for
ARTAGs (Fig. 6), and in those areas, most ARTAGs
were thorn-shaped astrocytes. However, ARTAGs were
also observed in other brain regions. Nevertheless, the
role of ARTAGs remains poorly understood. Because
common neurodegenerative pathology is limited in
supercentenarians, the presence of ARTAGs could affect
clinical and neurological conditions of supercentenar-
ians. However, further analysis is necessary to clarify
ARTAG pathology in supercentenarians.
TDP-43 deposition is emphasized in the hippocampus
and parahippocampus in aged individuals [2]. Basal fore-
brain TDP-43 pathology is also strongly associated with
hippocampal sclerosis-related aging, which is one of the
most important pathological changes indicating demen-
tia [2, 3, 47, 48] and AD pathology [49, 50] in aged indi-
viduals. TDP-43 pathology of the hippocampus and
parahippocampus was observed in two out of four cases.
In Case 1, TDP-43 pathology was only observed in the
basal forebrain. Again, hippocampal sclerosis or AD was
not diagnosed in the four supercentenarians. Although
TDP-43 pathology has been reported in the uncus in
normal aging individuals [51], our cases exhibited no se-
vere TDP-43 pathology in the uncus. Additionally, al-
though TDP-43 pathology is considered to spread in a
hierarchical manner in individuals with motor neuron
disease or frontotemporal lobar degeneration [52, 53],
our pathological results did not suggest either of these
diseases. Therefore, TDP-43 deposition in our cases
could be associated with the aging processes, although
the changes were relatively mild. Further studies are
needed to determine the pathological changes of TDP-
43 in supercentenarian brains.
Arteriolosclerosis was consistently observed, but it was
not very severe in the four cases (Table 3). A recent
study mentioned that brain arteriolosclerosis could be
associated with TDP-43 deposition in the amygdala and
limbic system, as well as hippocampal sclerosis [3]. This
pathological condition was termed “cerebral age-related
TDP-43 pathology and arteriolosclerosis” (CARTS) [3].
Based on this concept, Cases 1 and 2 were at the early
clinical stage of CARTS. However, Cases 3 and 4 were at
the preclinical stage, and no hippocampal sclerosis was
observed in all cases. Therefore, CARTS or hippocam-
pus sclerosis-related aging pathology was a mild condi-
tion in the supercentenarians. Because the right cerebral
hemispheres in all cases were stored as frozen tissue and
were not analyzed, it is important to keep in mind that
hippocampus sclerosis-related aging could exist in the
right hemisphere.
There are some limitations in the present study. Be-
cause all individuals were only visited once or twice by
one of the authors, we were not able to obtain detailed
clinical information. Also, because neuroimaging studies
were not performed, we could not report clinical, neuro-
radiological, or neuropathological correlations in the
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present study. We would like to emphasize, however,
that it is difficult to obtain autopsies from such ex-
tremely old individuals, because they are usually placed
in nursing homes or elderly care facilities in Japan.
Conclusions
Neuropathological alterations associated with aging were
relatively mild to moderate in the supercentenarian
brain. Considering their extremely old age, the individ-
uals might have some neuroprotective factors against
aging. In fact, AD pathological changes of NIA-Reagan
and NIA-AA criteria remained low to intermediate in all
cases. Future prospective studies and extensive molecu-
lar analyses are needed to determine the mechanisms of
human longevity. Because we have sufficient frozen tis-
sue from these supercentenarians, we welcome super-
centenarian research collaborations.
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